NCT00531180 is a Phase 2 clinical trial of 4D CT scans in Esophageal Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00531180?

NCT00531180 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00531180?

Interventions in NCT00531180: 4D CT scans, Lung Function Imaging.

What condition does NCT00531180 study?

NCT00531180 studies Esophageal Cancer, Lung Cancer.

Is NCT00531180 still recruiting?

NCT00531180 is currently completed. Last updated 25 October 2018.

Last reviewed 2018-10-25 · How we verify

NCT00531180

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies

Completed Phase 2 Last updated 25 October 2018

What this trial tests

Phase 2 trial testing 4D CT scans in Esophageal Cancer in 31 participants. Completed in 21 September 2018.

Timeline

21 August 2007

Primary endpoint
21 September 2018

21 September 2018

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	31
Start date	21 August 2007
Primary completion	21 September 2018
Estimated completion	21 September 2018
Sites	1 location across United States

Drugs / interventions tested

4D CT scans
Lung Function Imaging

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Esophageal Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: Primary Objective: 1\. To determine the correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation. Secondary Objective: 1. To evaluate the reproducibility of the 4D CT derived ventilation and to obtain an estimate of the variance in a single setting. 2. To assess the correlation between hypoperfused and hypoventilated pulmonary regions in patients with thoracic malignancies. 3. To investigate the effect of continuous positive airway pressure (CPAP) on ventilation and tumor motion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in CT-based lung function imaging for thoracic radiotherapy.
Bi S, Yuan Q, Dai Z, Sun X, et al · · 2024 · cited 4× · PMID 39286020 · DOI 10.3389/fonc.2024.1414337

Verify or expand the search:

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00531180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 25 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00531180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing